Ulipristal Acetate Gedeon Richter

RSS

Withdrawn

This medicine's authorisation has been withdrawn

ulipristal acetate
MedicineHumanWithdrawn

Czech is available via eTranslation, the European Commission's machine translation service.

Translate to Czech | Important information about machine translation

  • Application under evaluation
  • CHMP opinion
  • European Commission decision

Overview

On 14 June 2021, the European Commission withdrew the marketing authorisation for Ulipristal Acetate Gedeon Richter (ulipristal acetate) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Gedeon Richter Plc., which notified the European Commission of its decision not to market the product in the EU for commercial reasons. 

Ulipristal Acetate Gedeon Richter was granted marketing authorisation in the EU on 27 August 2018 for the treatment of uterine fibroids. The marketing authorisation was initially valid for a 5-year period. 

Ulipristal Acetate Gedeon Richter was a duplicate application to Esmya, which is marketed in several EU countries. 

The European Public Assessment Report (EPAR) for Ulipristal Acetate Gedeon Richter is updated to indicate that the marketing authorisation is no longer valid.

български (BG) (805.8 KB - PDF)

Zobrazit

español (ES) (708.53 KB - PDF)

Zobrazit

čeština (CS) (781.02 KB - PDF)

Zobrazit

dansk (DA) (705.89 KB - PDF)

Zobrazit

Deutsch (DE) (711.46 KB - PDF)

Zobrazit

eesti (ET) (694.54 KB - PDF)

Zobrazit

ελληνικά (EL) (805.14 KB - PDF)

Zobrazit

français (FR) (710.29 KB - PDF)

Zobrazit

hrvatski (HR) (734.95 KB - PDF)

Zobrazit

italiano (IT) (706 KB - PDF)

Zobrazit

latviešu (LV) (156.85 KB - PDF)

Zobrazit

lietuvių (LT) (733.64 KB - PDF)

Zobrazit

magyar (HU) (779.92 KB - PDF)

Zobrazit

Malti (MT) (793.31 KB - PDF)

Zobrazit

Nederlands (NL) (707.03 KB - PDF)

Zobrazit

polski (PL) (781.89 KB - PDF)

Zobrazit

português (PT) (698.7 KB - PDF)

Zobrazit

română (RO) (734.45 KB - PDF)

Zobrazit

slovenčina (SK) (784.27 KB - PDF)

Zobrazit

slovenščina (SL) (779.14 KB - PDF)

Zobrazit

suomi (FI) (705.48 KB - PDF)

Zobrazit

svenska (SV) (706.53 KB - PDF)

Zobrazit

български (BG) (805.8 KB - PDF)

Zobrazit

español (ES) (708.53 KB - PDF)

Zobrazit

čeština (CS) (781.02 KB - PDF)

Zobrazit

dansk (DA) (705.89 KB - PDF)

Zobrazit

Deutsch (DE) (711.46 KB - PDF)

Zobrazit

eesti (ET) (694.54 KB - PDF)

Zobrazit

ελληνικά (EL) (805.14 KB - PDF)

Zobrazit

français (FR) (710.29 KB - PDF)

Zobrazit

hrvatski (HR) (734.95 KB - PDF)

Zobrazit

italiano (IT) (706 KB - PDF)

Zobrazit

latviešu (LV) (156.85 KB - PDF)

Zobrazit

lietuvių (LT) (733.64 KB - PDF)

Zobrazit

magyar (HU) (779.92 KB - PDF)

Zobrazit

Malti (MT) (793.31 KB - PDF)

Zobrazit

Nederlands (NL) (707.03 KB - PDF)

Zobrazit

polski (PL) (781.89 KB - PDF)

Zobrazit

português (PT) (698.7 KB - PDF)

Zobrazit

română (RO) (734.45 KB - PDF)

Zobrazit

slovenčina (SK) (784.27 KB - PDF)

Zobrazit

slovenščina (SL) (779.14 KB - PDF)

Zobrazit

suomi (FI) (705.48 KB - PDF)

Zobrazit

svenska (SV) (706.53 KB - PDF)

Zobrazit

Product information

български (BG) (1.87 MB - PDF)

Zobrazit

español (ES) (1006.84 KB - PDF)

Zobrazit

čeština (CS) (980.38 KB - PDF)

Zobrazit

dansk (DA) (985.58 KB - PDF)

Zobrazit

Deutsch (DE) (1.04 MB - PDF)

Zobrazit

eesti (ET) (931.37 KB - PDF)

Zobrazit

ελληνικά (EL) (1.98 MB - PDF)

Zobrazit

français (FR) (1018.25 KB - PDF)

Zobrazit

hrvatski (HR) (1.07 MB - PDF)

Zobrazit

italiano (IT) (974.64 KB - PDF)

Zobrazit

latviešu (LV) (1.8 MB - PDF)

Zobrazit

lietuvių (LT) (1.8 MB - PDF)

Zobrazit

magyar (HU) (1.56 MB - PDF)

Zobrazit

Malti (MT) (1.62 MB - PDF)

Zobrazit

Nederlands (NL) (967.06 KB - PDF)

Zobrazit

polski (PL) (1.59 MB - PDF)

Zobrazit

português (PT) (987.36 KB - PDF)

Zobrazit

română (RO) (1.09 MB - PDF)

Zobrazit

slovenčina (SK) (1.55 MB - PDF)

Zobrazit

slovenščina (SL) (1.5 MB - PDF)

Zobrazit

suomi (FI) (1013.08 KB - PDF)

Zobrazit

svenska (SV) (948.19 KB - PDF)

Zobrazit

Íslenska (IS) (975.68 KB - PDF)

Zobrazit

norsk (NO) (973.21 KB - PDF)

Zobrazit
14/06/2021
icon globe

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

български (BG) (640.72 KB - PDF)

Zobrazit

español (ES) (597.33 KB - PDF)

Zobrazit

čeština (CS) (622.2 KB - PDF)

Zobrazit

dansk (DA) (596.79 KB - PDF)

Zobrazit

Deutsch (DE) (597.21 KB - PDF)

Zobrazit

eesti (ET) (597 KB - PDF)

Zobrazit

ελληνικά (EL) (640.57 KB - PDF)

Zobrazit

français (FR) (597.63 KB - PDF)

Zobrazit

hrvatski (HR) (606.66 KB - PDF)

Zobrazit

italiano (IT) (596.99 KB - PDF)

Zobrazit

latviešu (LV) (634.12 KB - PDF)

Zobrazit

lietuvių (LT) (617.71 KB - PDF)

Zobrazit

magyar (HU) (629.46 KB - PDF)

Zobrazit

Malti (MT) (630.46 KB - PDF)

Zobrazit

Nederlands (NL) (597.66 KB - PDF)

Zobrazit

polski (PL) (622.63 KB - PDF)

Zobrazit

português (PT) (597.51 KB - PDF)

Zobrazit

română (RO) (616.82 KB - PDF)

Zobrazit

slovenčina (SK) (622.69 KB - PDF)

Zobrazit

slovenščina (SL) (621.01 KB - PDF)

Zobrazit

suomi (FI) (597.62 KB - PDF)

Zobrazit

svenska (SV) (590.12 KB - PDF)

Zobrazit

Íslenska (IS) (597.28 KB - PDF)

Zobrazit

norsk (NO) (597.55 KB - PDF)

Zobrazit

Product details

Name of medicine
Ulipristal Acetate Gedeon Richter
Active substance
ulipristal acetate
International non-proprietary name (INN) or common name
ulipristal acetate
Therapeutic area (MeSH)
Leiomyoma
Anatomical therapeutic chemical (ATC) code
G03XB02

Pharmacotherapeutic group

Sex hormones and modulators of the genital system

Therapeutic indication

Ulipristal acetate is indicated for one treatment course of pre-operative treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age.

Ulipristal acetate is indicated for intermittent treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age who are not eligible for surgery.

Authorisation details

EMA product number
EMEA/H/C/005017
Marketing authorisation holder
Gedeon Richter Plc.

Gyomroi ut 19-21
1103 Budapest
Hungary

Opinion adopted
28/06/2018
Marketing authorisation issued
27/08/2018
Revision
1

Assessment history

български (BG) (1.16 MB - PDF)

Zobrazit

español (ES) (717.52 KB - PDF)

Zobrazit

čeština (CS) (1.08 MB - PDF)

Zobrazit

dansk (DA) (776.12 KB - PDF)

Zobrazit

Deutsch (DE) (809.32 KB - PDF)

Zobrazit

eesti (ET) (780.64 KB - PDF)

Zobrazit

ελληνικά (EL) (1.12 MB - PDF)

Zobrazit

français (FR) (724.64 KB - PDF)

Zobrazit

hrvatski (HR) (851.47 KB - PDF)

Zobrazit

italiano (IT) (1.33 MB - PDF)

Zobrazit

latviešu (LV) (1.01 MB - PDF)

Zobrazit

lietuvių (LT) (869.2 KB - PDF)

Zobrazit

magyar (HU) (988.65 KB - PDF)

Zobrazit

Malti (MT) (1.05 MB - PDF)

Zobrazit

Nederlands (NL) (710.99 KB - PDF)

Zobrazit

polski (PL) (1.01 MB - PDF)

Zobrazit

português (PT) (719.58 KB - PDF)

Zobrazit

română (RO) (879.76 KB - PDF)

Zobrazit

slovenčina (SK) (1013.26 KB - PDF)

Zobrazit

slovenščina (SL) (1001.18 KB - PDF)

Zobrazit

suomi (FI) (704.64 KB - PDF)

Zobrazit

svenska (SV) (709.6 KB - PDF)

Zobrazit

Íslenska (IS) (708.37 KB - PDF)

Zobrazit

norsk (NO) (699.99 KB - PDF)

Zobrazit

This page was last updated on

Share this page